Impact of treatment on overall survival (OS) in higher-risk myelodysplastic syndromes (MDS): A report from the erasme study.

dc.contributor.author	Albors Ferreiro, Manuel
dc.date.accessioned	2017-06-07T07:34:21Z
dc.date.available	2017-06-07T07:34:21Z
dc.date.issued	2015
dc.identifier.issn	0006-4971
dc.identifier.uri	http://hdl.handle.net/20.500.11940/8098
dc.language.iso	eng
dc.title	Impact of treatment on overall survival (OS) in higher-risk myelodysplastic syndromes (MDS): A report from the erasme study.
dc.type	Publicación de congreso
dc.authorsophos	Arnan M.
dc.authorsophos	Coll R.
dc.authorsophos	Tormo M.
dc.authorsophos	Bastida J.M.
dc.authorsophos	Calbacho M.
dc.authorsophos	Bernal T.
dc.authorsophos	Ramos F.
dc.authorsophos	Somolinos N.
dc.authorsophos	Pedro C.
dc.authorsophos	Albors M.
dc.authorsophos	Marchante I.
dc.authorsophos	Brunet S.
dc.authorsophos	Rafel M.
dc.authorsophos	Valcarcel D
dc.identifier.isi	368021804216
dc.identifier.sophos	19447
dc.issue.number	23
dc.journal.title	Blood
dc.organization	Servizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Ourense - Complexo Hospitalario Universitario de Ourense::Hematoloxía clínica
dc.rights.accessRights	openAccess
dc.typesophos	Comunicaciones a congresos
dc.volume.number	126

Files in this item

Files	Size	Format	View
There are no files associated with this item.